Videos

CorMatrix Cardiovascular Receives Two U.S. Patents for Biomaterial Compositions

CorMatrix Cardiovascular Receives Two U.S. Patents for Biomaterial Compositions

Patents cover grafts, compositions comprising various extracellular matrix materials.

10.09.15
CorMatrix Cardiovascular Inc. has been granted two U.S. patents for extracellular matrix (ECM) compositions.

One patent ("Articles for Tissue Regeneration with Biodegradable Polymers") covers grafts and compositions composed of various ECM materials, including small intestine submucosa, stomach submucosa, liver basement membrane and urinary bladder submucosa. ECM biopolymer grafts and compositions also can include supplemental bioactive agents such as growth factors, cells, and other pharmacological agents.

A biodegradable polymer is useful to devices because it can hold an anatomically correct shape and retain a presence for a temporary period of time. These characteristics, when combined with CorMatrix ECM platform technology, enable new tissue to conform to a device while maintaining a position or shape during remodeling; and would remain until it is strong enough to fully support its new application in the body.

“The addition of various compositions of polymers in combination with the CorMatrix platform of ECM materials further broadens our potential applications. The compositions and devices that we are creating are unique in their cardiovascular and non-cardiovascular applications,” said Robert Matheny, M.D., chief scientific officer and co-founder of CorMatrix. “This patent enables us to pursue the ideal biomaterial—one that leaves no trace, is easily processed into its final anatomical product form, one that demonstrates acceptable shelf life, and is easily sterilized.”

The ideal polymer for a particular application requires configuration such that its mechanical and degradation properties match that of the application, remaining sufficiently strong until the surrounding tissue has healed. Historically, the use of traditional polymers has been disregarded due to inflammatory and toxic responses, and are not metabolized by the body after fulfilling their purpose.

The U.S. Patent and Trademark Office also granted CorMatrix a patent for another injectable ECM bioscaffold that includes an exogenously added cytokine, induces stem cell proliferation and differentiation of stem cells into cardiomyocytes, and, thereby, angiogenesis and remodeling, i.e. tissue repair, of cardiovascular tissue. That patent represents a growing number of multiple CorMatrix U.S. and foreign patents with claims directed to ECM bioscaffolds that are augmented with a variety of bioactive agents, such as TGF-α (transforming growth factor alpha), TGF-β (transforming growth factor beta) and RNA (ribonucleic acid).

“These recently issued patents emphasize the drive, determination and vision of our people and our organization,” said David Camp, CEO and co-founder of CorMatrix. “With this and other investments in U.S. and foreign patent applications, we’ll continue to drive ECM-based compositions aimed at extending our CorMatrix platform and changing the medical device industry.”

CorMatrix has received 51 U.S. and foreign patents in the last two years for its ECM-based compositions and structures.

CorMatrix Cardiovascular, Inc. is a privately held developer of biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues. CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as an alternative to synthetic or cross-linked materials. Headquartered in Roswell, Ga., the company is currently researching, developing and commercializing ECM for various cardiovascular and other indications. Since its launch in 2006, the firm's ECM technology has been used in more than 825 hospitals across America and implanted in more than 110,000 cardiac procedures.

Watch the video below to learn more about the ways ECM technology can help repair damaged heart tissue:


Related Searches:
Suggested For You

Related Breaking News

    Loading, Please Wait..